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Franc¸aise de Greffe de Moelle et de Therapie Cellulaire
Anne Sirvent,1 Nathalie Dhedin,2 Mauricette Michallet,3 Nicolas Mounier,1
Catherine Faucher,4 Ibrahim Yakoub-Agha,5 Mohamad Mohty,6 Marie Robin,7 Reza Tabrizi,8
Laurence Clement,9 Karin Bilger,10 Fabrice Larosa,11 Nathalie Contentin,12 Anne Huyn,13
Sylvie Franc¸ois,14 Claude-Eric Bulabois,15 Patrice Ceballos,16 Jean-Henri Bourrhis,17
Agne`s Buzyn,18 Jeroˆme Cornillon,19 Gaelle Guillerm,20 Thierry de Revel,21
Jacques-Olivier Bay,22 Franc¸ois Guilhot,23 Noe¨l Milpied7,8Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis.
However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT).
The purpose of this study was to assess the outcome of all adult patients with DLBCL whose treatment in-
cluded a reduced-intensity conditioning (RIC) regimen for allogeneic SCTand whose data were reported in
the French Society of Marrow Transplantation and Cellular Therapy registry. Sixty-eight patients (median age:
48 years) were transplanted from October 1998 to January 2007. They had received a median of 2 regimens
of therapy prior to allogeneic SCT, and 54 (79%) had already undergone SCT. Prior to transplantation, 32
patients (47%) were in complete remission (CR). For all patients but 1, conditioning regimens were based
on fludarabine (Flu), which was combined with other chemotherapy drugs in 50 cases (74%) and with total
body irradiation (TBI) in 17 (25%). For 56 patients (82%), the donor was an HLA-matched sibling, and periph-
eral blood was the most widely used source of stem cells (57 patients, 84%). With a median follow-up of 49
months, estimated 2-year overall survival (OS), progression-free survival (PFS), and the cumulative incidence
of relapse were 49%, 44%, and 41%, respectively. The 1-year cumulative incidence of nonrelapse mortality
(NRM) was 23%. According to multivariate analysis, the patients in CR before transplantation had a signifi-
cantly longer PFS and a lower CI of relapse than patients transplanted during partial remission or stable or
progressive disease. These results suggest that reduced-intensity allergenic transplantation is an attractive
therapeutic option for patients with high-risk DLBCL.
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Fifty percent to 60% of patients with diffuse large B
cell lymphoma (DLBCL) are cured by first-line treat-
ment combining anthracycline-based chemotherapy
with rituximab [1]. A subset of patients whose response
is suboptimal or who relapse after their initial treat-
ment can be salvaged by high-dose chemotherapy fol-
lowed by autologous stem cell transplantation (SCT)
[2-4]. However, the poor prognosis of patients with ad-
verse risk factors at relapse, such as advanced stage,
chemorefractory disease, a short interval between
remission and relapse, or a relapse after high-dose ther-
apy and autologous SCT, underscores the need to
search for innovative therapeutic strategies [5-7].
Unlike autologous SCT, allogeneic SCT gener-
ates an allogeneic graft-versus-lymphoma effect that
reduces the likelihood of disease relapse following
transplantation [8,9]. However, in patients with lym-
phoma, standard myeloablative (MA) allogeneic SCT
has proved disappointing, essentially because its bene-
fit was usually offset by high nonrelapse mortality
(NRM) [10,11]. The advent of reduced-intensity con-
ditioning (RIC) regimens has renewed interest in allo-
geneic SCT, which reduces NRM while maintaining
a graft-versus-lymphoma effect, and therefore allows
the treatment of elderly patients and/or patients with
comorbidities [12-20]. Although RIC allogeneic
SCT has only been used for a few DLBCL patients,
the results suggest that this procedure may be benefi-
cial [19,20]. We therefore conducted a retrospective
study of the outcome of patients with DLBCL who un-
derwent allogeneic SCT after an RIC regimen and
were reported to the Registry of the Societe Franc¸aise
de Greffe de Moelle et de Therapie Cellulaire (SFGM-
TC),the French Society of Marrow Transplantation
and Cellular Therapy.PATIENTS AND METHODS
Patients
We included in this study all patients whose data
were reported in the SFGM-TC registry and who ful-
filled the following criteria: diagnosis of DLBCL
occurring de novo or after transformation from indo-
lent non-Hodgkin’s lymphoma, age at transplantation
$16 years, and RIC regimen prior to allogeneic
transplantation. Histologic diagnosis was based on
local review. Information concerning histopathologic
parameters, recipients’ clinical history, presentation
and treatment, disease status at the time of transplanta-
tion, donors, source of hematopoietic stem cells, trans-
plant procedures and follow-up had been obtained
from the PROMISE database. All participating centers
had been thereafter requested to validate these data be-
fore patients were included in the study.Study Endpoints
The primary endpoints of the study were overall
survival (OS), progression-free survival (PFS), and
the cumulative incidence of relapse. Other endpoints
were NRM and the incidence of acute and chronic
graft-versus-host disease (aGVHD, cGVHD).
Statistical Analysis
Demographic and baseline laboratory data were
compared among subpopulations by Fisher’s exact
test for nominal variables and Wilcoxon’s rank sum
test for continuous variables. PFS was calculated
from the date of graft to that of disease progression,
relapse, or death. OS was measured from the date of
graft until death, from whatever cause. NRM was de-
fined as death without relapse. Death occurring after
relapse was always ascribed to disease. Survival func-
tions were estimated by the Kaplan-Meier method
and compared by the log-rank test. Cumulative inci-
dences were estimated using competing risks analysis,
where nonrelapse deaths and progression or relapse
were the competing risks [21]. Multivariate analysis
was performed using the Cox model. Differences be-
tween the results of comparative tests were considered
significant if the 2-sided P-value was\.05. All statisti-
cal analyses were performed using SAS 9.1 software
(SAS Institute, Cary, NC) and Splus 6.2 software
(MathSoft, Cambridge, MA).RESULTS
Patient and Transplant Characteristics
Sixty-eight patients from 23 transplant centers
underwent RIC allogeneic SCT from October 1998
to January 2007 (Table 1). Data were analyzed in
May 2008. Patient and transplant characteristics are
given in Table 1. The median age of the cohort at trans-
plant was 48 years (range: 17-66). The median number
of pretransplant therapeutic regimens was 2 (range: 1–
5). Twenty-seven (40%) patients had received rituxi-
mab prior to transplantation. Rituximab was not used
during conditioning regimen in any patients. The addi-
tion of rituximab to any chemotherapeutic program ei-
ther as front line or as salvage before the allogeneic
stem cell transplantation was not retrieved from the in-
dividual patient’s data. Before allogeneic SCT, 54 pa-
tients (79%) had received 1 or more autologous or
allogeneic transplantations. The median period from
diagnosis to allogeneic SCT was 22 months (range:
5-125). At the time of allogeneic SCT, 36 patients
(53%) had not achieved complete remission (CR).
CR was assessed by the absence of detectable disease
on clinical examination and CT-scan. No routine
molecular biology or dynamic imaging methods were
used. Donors for 56 patients (83%) were HLA-
Table 1. Patient and Transplant Characteristics
Characteristic
No. of Patients
(N5 68) %
Sex
Male 43 63
Female 25 37
Age, years
Median 48
Range (17-66)
Time from diagnosis to SCT, months
Median 22
Range (5-125)
# 12 months 11 16
Prognostic factors at diagnosis
IPI > 1 32 (12*) 47
DLBCL transformed from indolent NHL 14 (2*) 21
Prior treatment
> 2 chemotherapy regimes 25 37
Prior anti-CD20 monoclonal antibodies 27(1*) 40
Prior transplantation 54† 79
Disease status at SCT
CR 32 47
PR 23 34
Stable or PD 13 19
Conditioning regimen
Fludarabine-based—no TBI 50 74
Fludarabine-based + TBI 2Gy 17 25
Cyclophosphamide—TBI 6Gy 1 1
T cell depletion in conditioning 38 56
ATG 36
monoclonal antibody 2
Source of stem cells
Peripheral blood 57 84
Bone marrow 10 15
Cord blood 1 1
Donor
Matched related 56 82
Matched unrelated 8 12
Mismatched unrelated 4 6
GVHD prophylaxis
Cyclosporine alone 24 35
Cyclosporine + MMF 24 35
Cyclosporine + methotrexate 15 22
Other 5 7
SCT indicates, stem cell transplantation; LDH, lactate dehydrogenase;
IPI, International Prognostic Index;DLBCL, diffuse large B cell lymphoma;
NHL, non-Hodgkin lymphoma; CR, complete remission; PR, partial
remission; MMF, mycophenolate mofetil; GVHD, graft-versus-host dis-
ease; TBI, total body irradiation; Gy, Gray; ATG, antithymocyte globulin.
*Missing data.
†One patient received a prior allogeneic transplantation.
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blood (PB) was the source of stem cells. Conditioning
regimens were fludarabine (Flu)-based and were mostly
combined, either with chemotherapy (50 patients,
74%) or with 2-Gray total body irradiation (TBI) (17
patients, 25%). Most radiation-free conditioning regi-
mens combined either Flu 150 mg/m2 with busulfan
(Bu) 8 mg/kg (34 patients) or Flu 120 mg/m2 with
cyclophosphamide (Cy) 60 mg/kg (8 patients) and/or
Flu 125 mg/m2 with melphalan (Mel) 140 mg/m2
(5 patients). Other conditioning regimens included
the combinations idarubicin (36 mg/m2)-cytarabine
(6 g/m2)-Flu (120 mg/m2) in 2 patients and Bu
(8 mg/kg)-Cy (60 mg/kg)-Flu (60 mg/m2) in 1 patient.
Radiation-containing regimens consisted in theassociation of Flu 90 mg/m2 with 2-Gray TBI in 16 pa-
tients or Flu 200 mg/m2 and Cy 50 mg/kg with
2-Gray TBI in 1 patient or Cy 60 mg/kg with 6-Gray
TBI in 1 patient.
Survival
Of the 68 patients included in this retrospective
analysis, 36 died, and 32 were alive at the time of the
last analysis after a median follow-up of 49 months
(range: 10-96), 30 of them without any evidence of
lymphoma at the last follow-up. The first cause of
death was lymphoma, in 20 patients. Two-year OS
and PFS for the entire group were respectively 49%
(95% CI, 37% to 61%) and 44% (95% CI, 32% to
56%; Figure 1).
By univariate analysis, OS was significantly better
for patients transplanted during CR, with a graft
from a related donor, and for those who did not de-
velop grade III to IV aGVHD or cGVHD (Table 2).
By multivariate analysis, only grade 0 to II aGVHD
and cGVHD remained associated with a significantly
better OS (Table 3). CR status at the time of transplan-
tation was the only variable that affected PFS favor-
ably, by both analyses (Figure 2).
When OS and PFS were analyzed according to the
pretransplant status, that is, CR versus partial remis-
sion (PR) versus stable or progressive disease, we
found, by univariate analysis, that OS was significantly
better in patients transplanted in CR (64% versus 38%
versus 28%, P5 .049, hazard ratio [HR]5 1.02) and
that although patients transplanted in CR had a better
PFS, the difference did not reach statistical signifi-
cance (59% versus 30% versus 29%, P5 .11).
NRM
The cumulative incidences of NRM at 100 days
and 1 year were respectively 14% (95% CI, 5% to
23%) and 23% (95% CI, 12% to 34%). Only 1 patient
in CR deceased more than 28 months post transplant
(Figure 3). Sixteen patients died of treatment-related
complications at a median of 127 days after transplant
(range: 13 to 1607). In this group, the main causes of
death were infection in 4 patients, multiorgan failure
in 4, GVHD in 5, and other forms of toxicity in 3.
Grade III-IV aGVHD adversely affected NRM on
univariate analysis (Table 2).
GVHD
aGVHD grade II to IV occurred in 26 of the 68 pa-
tients (39%); it was grade III to IV in 15 (22%). Among
the 58 patients who survived for .100 days, cGVHD
developed in 24 (41%).
Disease Recurrence or Progression
Twenty-six patients had relapsed or progressed at
a median of 3 months after transplant (range: 0-55)
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Figure 1. Overall survival (OS) and progression-free survival (PFS) of
the study population (n5 68).
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of the 26 patients were transplanted during CR, 13
during PR, and 7 during stable or progressive disease.
At the last follow-up, 20 patients had died of lym-
phoma, and 6 were still alive, 5 of them in CR after
treatment for relapse. This treatment was a combina-
tion of chemotherapy 6 radiotherapy 6 donor lym-
phocyte infusion. The 2-year cumulative incidence of
relapse was 41% (95% CI 28% to 54%; Figure 3).
CR status prior to transplant, and the use of pe-
ripheral blood as the source of stem cells, were associ-
ated with a significant decrease in the incidence of
relapse, by both univariate and multivariate analysis
(Tables 2 and 3). A trend toward a decreased incidence
of relapse was observed in patients who developed
chronic GVHD. When the incidence of relapse or dis-
ease progression was analyzed according to the pre-
transplant status, that is, CR versus PR versus stable
or progressive disease, we confirmed that patients in
CR had a lower incidence of relapse or disease progres-
sion: 20% versus 62% versus 58% (P5 .09).DISCUSSION
Patients with DLCBL who are refractory to front-
line treatment or who relapse after a first-line regimen
have a poor outcome. The best therapeutic responses
may be achieved by autologous SCT [2-4]. For relaps-
ing after SCT, other therapeutic options should be
proposed, with the main aim of reducing the incidence
of lymphoma recurrence. Many reports have con-
firmed the feasibility of allogeneic hematopoietic
transplantation following an MA or nonmyeloablative
(NMA) regimen for patients with lymphoma whose
conventional therapy has failed [10-20]. The rationale
of this therapeutic approach is based on the use of
a tumor-free graft and the immune-mediatedgraft-versus-lymphoma (GVL) effect [8,9]. However,
information is still limited regarding the results of allo-
geneic transplantation in patients with aggressive lym-
phoma, mainly because of the heterogeneity of the
histologic types of lymphoma included in the pub-
lished reports [11,13,22,23]. The present retrospective
registry study, with a long median follow-up of 49
months for survivors, was exclusively confined to pa-
tients with a single type of histology, who were all
treated by RIC allogeneic SCT.
Our patients had an elevated median age and un-
derwent intensive pretransplant chemotherapy
regimens: indeed, 54 of 68 patients (79%) had 1 previ-
ous failed transplant, indicating a population at high
risk of NRM. Given the characteristics of our popula-
tion of patients, the 23% cumulative NRM incidence
we found at 1 year compared favorably with that re-
ported for other investigated series of patients on non-
myeloablative regimens (Table 4) [12,14-20]. Patients’
age, prior SCT, and patient-donor relationships,
which are significant determinants of NRM after con-
ventional allografting, did not affect NRM in our
study, thus confirming that for medically unfit pa-
tients, nonmyeloablative regimens were a feasible al-
ternative. In this study, severe grade III to IV
aGVHD, which occurred in 22% of patients, was the
only prognostic factor strongly correlated with
NRM. Two-year OS was 49% and was adversely af-
fected by the presence of grade III to IV aGVHD
and the absence of cGVHD. Surprisingly, disease sta-
tus at transplant, which greatly affects the PFS and re-
lapse incidences, was not correlated with OS, possibly
because donor lymphocyte infusion (DLI), new agents
such as rituximab, more appropriate palliative chemo-
therapy, or excellent supportive care may have im-
proved the survival of patients who relapsed after
transplant.
In previously published studies of RIC allogeneic
SCT, the rates of relapse at 2 or 3 years ranged from
33% to 79% for patients with high-grade non-
Hodgkin lymphoma (NHL), and were consistent
with our results (Table 4) [13,15,18-20]. Given the
poor prognosis of this subset of patients when treated
by conventional therapy, the results of all these studies
can be considered encouraging. Nevertheless, disease
recurrence remained the first cause of treatment fail-
ure. As previously reported, the incidences of disease
recurrence and PFS did not differ, whether patients
had de novo lymphoma or DLBCL transformed
from indolent lymphoma [20]. However, such recur-
rence was often observed soon after SCT. Here, 16/
26 patients were diagnosed as having relapse or disease
progression during the first 6 months after SCT. Con-
sequently, great efforts should be made to reduce this
excessively high incidence of early relapse, which
occurs during the few weeks necessary to establish
a robust graft-versus-lymphoma effect. As shown by
Table 2. Risk Factors for Overall Survival, Progression-Free Survival, Relapse, and Nonrelapse Mortality on Univariate Analysis
OS PFS Relapse NRM
Variable 2-year OS (%) RR P 2-year PFS (%) RR P 2-year rel (%) RR P 2-years NRM (%) RR P
Age
# 45 years 49 0.94 .85 42 1.02 .94 44 0.86 .7 19 1.08 .89
> 45 years 49 45 36 25
Sex
Male 49 0.96 .89 42 0.82 .54 41 0.87 .74 28 0.65 .47
Female 50 48 40 14
Time from diagnosis to SCT
# 2 years 44 0.61 .16 45 0.83 .55 41 0.82 .61 24 0.75 .59
> 2 years 55 43 42 22
Number of chemotherapy regimes before SCT
# 2 46 0.78 .49 44 1.05 .87 44 0.84 .67 21 1.25 .68
> 2 55 44 34 26
IPI
# 1 50 1.14 .73 46 1.24 .55 37 1.23 .67 27 0.91 .86
> 1 53 47 35 24
Histologic transformation
De novo DLBCL 45 0.59 .27 40 0.66 .32 44 0.79 .64 27 0.26 .19
Transformed indolent NHL 64 57 41 8
Anti-CD20 therapy before SCT
No 47 0.89 .74 40 0.84 .59 45 0.93 .85 27 0.62 .42
Yes 50 48 37 18
Transplant before SCT
No 55 1.19 .68 57 1.43 .39 31 1.55 .42 17 0.96 .95
Yes 48 40 44 24
Disease status at SCT
CR 66 2.27 .02 59 2.32 .01 20 3.92 .00 21 1.14 .80
PR/SD/PD 34 30 61 24
TBI conditioning
No 45 0.80 .57 44 1.10 .77 40 1.01 .99 23 1.08 .89
Yes 61 44 41 25
Source of stem cells
PBSC 52 1.65 .24 47 2.14 .06 36 3.29 .01 24 0.56 .58
Other 36 27 70 9
Donor
Related 53 2.34 .04 46 1.67 .2 41 1.24 .7 19 2.85 .08
Unrelated 33 33 36 47
T cell depletion
No 56 1.13 .72 46 1.08 .80 40 1.3 .52 22 0.77 .63
Yes 43 42 42 24
aGVHD
Grade 0-II 56 2.38 .02 49 1.53 .23 41 0.78 .64 14 4.28 .01
Grade III-IV 27 27 43 52
cGVHD
No 38 0.43 .03 34 0.51 .05 50 0.47 .09 28 0.53 .29
Yes 70 63 27 14
SCT indicates stem cell transplantation; IPI, international prognostic index; NHL, non-Hodgkin lymphoma; CR, complete remission; PR, partial remis-
sion; SD, stable disease; PD, progressive disease; TBI, total body irradiation; PBSC, peripheral blood stem cell; cells aGVHD, acute graft-versus-host
disease; cGVHD, chronic graft-versus-host disease; OS, overall survival; PFS, progression-free survival; rel, relapse; NRM, nonrelapse mortality; RR, rel-
ative risk.
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allogeneic transplant did not significantly affect the
incidences of disease progression or relapse. Our re-
sults are in apparent contradiction with those of at least
2 studies, which stressed the poor prognosis of patients
rechallenged with rituximab in the setting of salvage
therapy and autologous transplantation [24,25]. Possi-
ble explanations for these contradictory results include
(1) our study concerned allotransplanted patients, and
(2) it was a registry study that lacked data on the timing
of rituximab use during the clinical course, in
particular, whether rituximab was administered during
the initial treatment and/or during the salvage therapy
[4,24,25]. As shown by our study, disease status attransplant (ie, complete versus partial remission) was
a major prognostic factor for relapse and PFS, suggest-
ing that pretransplant treatments that eradicate the un-
derlying malignancy more effectively before the
procedure may improve outcome [18,20,23]. For pa-
tients not in CR at transplant, a more aggressive strat-
egy using either tandem autologous-allogeneic SCT
or an MA regimen could be proposed [11,22,26-28].
Thus, several studies whose authors compared the re-
sults of MA and RIC regimens in patients with NHL
showed a lower risk of disease progression after a mye-
loablative regimen; this, however, was counterbal-
anced by a higher NRM, resulting in similar OS and
PFS [29,30]. Nevertheless, it seems that the reduced
Table 3. Results of Multivariate Analysis for Overall Survival, Progression-Free Survival, and Relapse
Outcome Variable Relative Risk 95% Confidence interval P value
OS aGVHD
Grade III-IV versus 0-II 2.29 [1.12; 4.69] .02
cGVHD
No versus Yes 2.28 [1.07; 4.85] .03
Disease status at SCT
PR/SD/PD versus CR 1.97 [0.98; 3.96] .06
Donor
Unrelated versus Related 1.44 [0.42; 4.96] .56
PFS cGVHD
No versus Yes 1.79 [0.90; 3.57] .09
Disease status at SCT
PR/SD/PD versus CR 2.32 [1.24; 4.33] .01
Source of stem cells
Other versus PBSC 1.47 [0.66; 3.29] .35
Relapse Disease status at SCT
PR/SD/PD versus CR 3.46 [1.37; 8.48] .009
Source of stem cells
Other vs PBSC 2.51 [1.02; 6.10] .04
OS indicates overall survival; PFS, progression-free survival; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; SCT,
stem cell transplantation;CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; PBSC, peripheral blood stem cell.
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patients with a HCT-specific comorbidity index score
of $1, implying that medically fit patients not in CR
may tolerate an MA regimen and should be enrolled
in randomized prospective trials to determine the op-
timal conditioning regimen [31].0 1 2 3 4 5
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Figure 2. Overall survival (OS) and progression-free survival (PFS) ac-
cording to status of disease at transplantation. CR, complete remission
group (n5 32); PR/SD/PD, partial remission/stable disease/progressive
disease group (n5 36).We were not able to demonstrate a clear graft-ver-
sus-lymphoma effect in our study: cGVHD was
strongly associated with improved OS, whereas there
was a weak correlation between PFS and cGVHD in
univariate analysis only. Because of the lack of data
on the timing of cGVHD in the database, this variable
could not be included as a time-dependent covariate in
the statistical analysis, which limited the significance of
our statistical results. Similarly, the data in our data-
base were insufficient to allow analysis of the response
to donor lymphocyte infusions. The graft-versus-lym-
phoma effect has been well described in patients with
indolent NHL [32]. By contrast, there is little evidence
in the literature of the efficacy of DLIs in the setting of
aggressive lymphoma. Case reports concerning the use
of donor lymphocyte infusions to treat overt relapse of
aggressive lymphoma only showed sporadic responses,
suggesting that the graft-versus-lymphoma effect is
cancelled out in rapidly growing malignancies0 1 2 3 4 5
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Figure 3. Cumulative incidence of nonrelapse mortality (NRM) and
relapse.
Table 4. Results of Published Studies on Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Aggressive non-
Hodgkin’s Lymphoma
Robinson et al.,
2002 [13]
Corradini et al.
2007 [23]
Rezvani et al.
2008 [19]
Thomson et al.,
2009 [20] Present study
Number of patients 62 61 (31*) 33 48 68
Median age (years) 43 51 52 46 48
Median number of prior lines of therapy 3 3 4 5 2
Patients with prior autoSCT 32 34 24 34 54
Patients in CR 45 chemosensitive 20 14 40 chemosensitive 32
OS (%) 47 (at 2 years) 69 (at 3 years) 45 (at 3 years) 47 (at 4 years) 49 (at 2 years)
PFS (%) 13 (at 2 years) 54 (at 3 years) 35 (at 3 years) 48 (at 4 years) 44 (at 2years)
Relapse/progression (%) 79 (at 2 years) 31 (at 3 years) 41 (at 3 years) 33 (at 2 years) 41 (at 2 years)
NRM (%) 30 (at 1 year) 15 (at 3 years) 25 (at 3 years) 32 (at 4 years) 23 (at 1 year)
SCT indicates stem cell transplantation; CR, complete remission; RIC, reduced-intensity conditioning; OS, overall survival; PFS, progression-free sur-
vival; NRM, nonrelapse mortality.
*Number of patients with diffuse large B cell lymphoma.
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such as positron emission tomography to identify pre-
transplant risk factors of posttransplant relapse, and/or
to detect posttransplant preclinical relapse or minimal
residual disease (MRD), may provide important prog-
nostic information enabling the early initiation of
adoptive immunotherapy consisting of prompt DLI
or monoclonal antibody (mAb) infusions, or a combi-
nation of both [35-39].
In summary, our findings confirm that NMA allo-
geneic transplantation can provide encouraging long-
term survival in a cohort of patients with relapsed or
refractory DLCBL. As disease recurrence strongly im-
pairs survival, efforts should be made to define the op-
timal timing for transplantation and the best
conditioning regimen, as well as to optimize the
GVL effect.ACKNOWLEDGMENTS
The authors thank Nathalie Dhedin and Mauric-
ette Michallet for critical review of the manuscript,
and Nicole Raus for data management. They also
thank Mathilde Dreyfus for editing the English.
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus
rituximab compared with CHOP alone in elderly patients with
diffuse large B-cell lymphoma. NEngl JMed. 2002;346:235-242.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone
marrow transplantation as compared with salvage chemotherapy
in relapses of chemotherapy-sensitive non Hodgkin’s lym-
phoma. N Engl J Med. 1995;333:1540-1545.
3. Mills W, Chopra R, McMillan A, Pearce R, Linch DC,
Goldstone AH. BEAM chemotherapy and autologous bone
marrow transplantation for patients with relapsed or refractory
non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588-595.
4. Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus
DHAP in relapsed patients with diffuse large B-cell lymphoma
(DLBCL) followed by stem cell transplantation and mainte-nance treatment with Rituximab or not: first interim analysis
on 200 patients. CORAL study. Blood. 2007;110:517a.
5. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted
International Prognostic Index predicts autologous stem cell
transplantation outcome for patients with relapsed or primary
refractory diffuse large B-cell lymphoma. Blood. 2003;102:
1989-1996.
6. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prog-
nostic value in patients with aggressive lymphoma enrolled onto
the Parma trial. J Clin Oncol. 1998;16:3264-3269.
7. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease af-
ter high-dose therapy and autologous transplantation for lym-
phoid malignancy: clinical course and patient follow-up. Blood.
1992;80:2142-2148.
8. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of
graft-versus-lymphoma effect associated with allogeneic bone
marrow transplantation. Blood. 1991;77:649-653.
9. Glass B, Nickelsen M, Dreger P, et al. Reduced-intensity condi-
tioning prior to allogeneic transplantation of hematopoietic
stem cells: the need for T cells early after transplantation to
induce a graft-versus-lymphoma effect. Bone Marrow Transplant.
2004;34:391-397.
10. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow
transplantation in patients who relapse after autologous trans-
plantation. Bone Marrow Transplant. 1997;20:859-863.
11. Dhedin N, Giraudier S, Gaulard P, et al. Allogeneic bone mar-
row transplantation in aggressive non-Hodgkin’s lymphoma
(excluding Burkitt and lymphoblastic lymphoma): a series of
73 patients from the SFGM database. Societe Franc¸aise de
Greffe de Moelle. Br J Haematol. 1999;107:154-161.
12. Khouri IF, Keating M, Korbling M, et al. Transplant-lite:
induction of graft-malignancy using fludarabine-based nonabla-
tive chemotherapy and allogeneic blood progenitor cell trans-
plantation as treatment for lymphoid malignancies. J Clin
Oncol. 1998;16:2817-2824.
13. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresist-
ant or aggressive lymphoma predicts for a poor outcome follow-
ing reduced-intensity allogeneic progenitor cell transplantation:
an analysis from the Lymphoma Working Party of the European
Group for Blood and Bone Marrow Transplantation. Blood.
2002;100:4310-4316.
14. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative
allogeneic hematopoietic transplantation: a promising salvage
therapy for patients with non-Hodgkin’s lymphoma whose dis-
ease has failed a prior autologous transplantation. J Clin Oncol.
2004;22:2419-2423.
15. Morris E, Thomson K, Craddock C, et al. Outcomes after alem-
tuzumab-containing reduced-intensity allogeneic transplanta-
tion regimen for relapsed and refractory non-Hodgkin’s
lymphoma. Blood. 2004;104:3865-3871.
16. Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hemato-
poietic stem-cell transplantation for malignant lymphoma:
Biol Blood Marrow Transplant 16:78-85, 2010 85Low NRM after AlloSCTa retrospective survey of 112 adult patients in Japan. Bone Mar-
row Transplant. 2005;36:205-213.
17. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation
with reduced-intensity conditioning for Hodgkin and non-
Hodgkin lymphoma: importance of histology for outcome.
Biol Blood Marrow Transplant. 2008;14:418-425.
18. Maloney DG. Allogeneic transplantation following nonmyeloa-
blative conditioning for aggressive lymphoma. Bone Marrow
Transplant. 2008;42:S35-S36.
19. Rezvani AR, Norasetthada L, Gooley T, et al. Non-myeloabla-
tive allogeneic haematopoietic cell transplantation for relapsed
diffuse large B-cell lymphoma: a multicentre experience. Br J
Haematol. 2008;143:395-403.
20. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term
survival after reduced-intensity allogeneic transplantation for
multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin
Oncol. 2009;27:426-432.
21. Gray RJ. A class of k-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
22. Freytes CO, Loberiza CO, Rizzo JD, et al. Myeloablative allo-
geneic hematopoietic stem cell transplantation in patients who
experience relapse after autologous stem cell transplantation
for lymphoma: a report of the International Bone Marrow
Transplant Registry. Blood. 2004;104:3797-3803.
23. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell
transplantation following reduced-intensity conditioning can
induce durable clinical and molecular remissions in relapsed
lymphoma: pre-transplant disease status and histotype heavily
influence outcome. Leukemia. 2007;21:2316-2323.
24. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy
for patients with relapsed or refractory diffuse large B-cell lym-
phoma: the influence of prior exposure to rituximab on outcome.
A GEL/TAMO study. Hematologica. 2008;93:1829-1836.
25. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine
and oxaliplatin: an effective salvage regimen for patients with
relapsed or refractory B-cell lymphoma not candidates for
high-dose therapy. Ann Oncol. 2007;18:1363-1368.
26. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haemato-
poietic stem-cell transplantation for relapsed and refractory
aggressive histology non-Hodgkin lymphoma. Br J Haematol.
2005;131:223-230.
27. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed
by nonmyeloablative immunosuppressive chemotherapy and
allogeneic peripheral-blood hematopoietic stem-cell transplan-
tation as treatment of resistant Hodgkin’s disease and non-
Hodgkin’s lymphoma. J Clin Oncol. 2000;18:3918-3924.
28. Buser AS,Stern M, Bucher C,et al. High-dose chemotherapy using
BEAM without autologous rescue followed by reduced-intensity
conditioning allogeneic stem-cell transplantation for refractory
or relapsing lymphomas:a comparison of delayed versus immediate
transplantation. Bone Marrow Transplant. 2007;39:335-340.29. Rodriguez R, Nademance A, Ruel N, et al. Comparison of re-
duced-intensity and conventional myeloablative regimens for
allogeneic transplantation in non-Hodgkin’s lymphoma. Biol
Blood Marrow Transplant. 2006;12:1326-1334.
30. Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising
outcomes in lymphoma patients treated with myeloablative or
nonmyeloablative conditioning and allogeneic hematopoietic
cell transplantation. Biol Blood Marrow Transplant. 2008;14:
538-545.
31. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ,
Storb R. Outcomes after allogeneic hematopoietic cell
transplantation with nonmyeloablative or myeloablative condi-
tioning regimens for treatment of lymphoma and chronic lym-
phocytic leukaemia. Blood. 2008;111:446-452.
32. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW,
Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma
effect of donor lymphocyte infusion in indolent lymphomas
relapsed after allogeneic stem cell transplantation. Bone Marrow
Transplant. 2003;32:1159-1163.
33. Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence of
a graft-versus-lymphoma effect against relapsed diffuse large-
B-cell lymphoma after allogeneic hematopoietic stem-cell trans-
plantation. Ann Oncol. 2008;19:1935-1940.
34. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the
long and winding road: how should it be traveled. Bone Marrow
Transplant. 2008;42:569-579.
35. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre-
and post-transplantation positron emission tomography using
18-fluorodeoxyglucose on poor-prognosis lymphoma patients
undergoing autologous stem cell transplantation. Cancer. 2007;
110:1361-1369.
36. Alousi AM, Saliba RM, Okoroji GJ, et al. Disease staging with
positron emission tomography or gallium scanning and use of
rituximab predict outcome for patients with diffuse large B-
cell lymphoma treated with autologous stem cell transplanta-
tion. Br J Haematol. 2008;142:786-792.
37. Hart DP, Avivi I, Thomson KJ, et al. Use of F-FDG positron
emission tomography following allogeneic transplantation to
guide adoptive immunotherapy with donor lymphocyte infu-
sions. Br J Haematol. 2005;128:824-829.
38. Dodero A, Crochiolo R, Patriarca F, et al. Prognostic value of
positron emission tomography (PET) scan in patients with
relapsed Hodgkin lymphoma or aggressive non-Hodgkin
lymphoma receiving salvage chemotherapy followed by
reduced-intensity allogeneic stem cell transplantation. Blood.
2007;110:3039a.
39. Yoshimi A, Izutsu K, Takahashi M, et al. Conventional alloge-
neic hematopoietic stem cell transplantation for lymphoma
may overcome the poor prognosis associated with a positive
FDG-PET scan before transplantation. Am J Hematol. 2008;
83:477-481.
